SBSean T. Berkowitz

Sean T. Berkowitz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sean T. Berkowitz has a total of 106 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Financial Impact of Antivascular Endothelial Growth Factor Drug Durability

    by Emily C. Davis, Tom Murickan, Ifrah Khurram, Sean T. Berkowitz, Charles Williard, Akshay S. Thomas

    Purpose: To examine the yearly cost of antivascular endothelial growth factor (anti-VEGF) therapy borne by patients and to assess the major contributors to patient cost. Methods: A retrospective, cross-sectional cost analysis was conducted of 29 250 insured patients in a single practice receiving anti-VEGF injections over a 21-month period between January 1, 2023, and September 30, 2024. Direct costs to the patient were abstracted, including patient copay and patient-responsible portions of imaging, medication, procedure, and visit costs; medication costs were based on average sales price. Transportation cost and opportunity cost associated with missed work were operationalized to estimate indirect costs, using age-stratified employment rates and median earnings from the United States Bureau of Labor Statistics for both patients and accompanying caregivers. Results: The mean (±SD) direct cost per visit was $91.72 ± $22.22. Indirect costs per visit varied by indication, with a mean indirect cost per visit of $97.89 for patients with neovascular age-related macular degeneration (AMD) and $164.44 for patients with diabetic macular edema (DME) for a half day of missed work, and $167.98 and $301.09, respectively, for a full day off work. Indirect costs accounted for 45.37% to 74.86% of total patient cost for a half day off, and 58.76% to 84.50% for a full day off. Relative to the baseline of 12 monthly bevacizumab injections received annually (half-day off scenario), the equivalent total patient cost accrued would correspond to a mean annual number of injections of 9.32 and 10.00 for aflibercept 2 mg, 11.09 and 11.35 for aflibercept 8 mg, and 9.05 and 9.78 for faricimab 6 mg in patients with neovascular AMD and patients with DME, respectively. Conclusions: Patient cost is driven more by visit frequency and its associated indirect costs than by drug price. Less frequent dosing with a more durable agent can therefore lower the total cost experienced by patients despite a higher acquisition price.

  • Open Access

    Intravitreal Anti-VEGF Injection Transitions Across Bevacizumab, Biosimilar, and Branded Medications: The IRIS Registry Study

    by Sean T. Berkowitz, Joshua B. Gilbert, Connor J. Ross, William C. Kearney, Alice Lorch, Joan W. Miller, Elizabeth J. Rossin, Paul Sternberg, Avni P. Finn

    Purpose: To characterize antivascular endothelial growth factor medication transitions among patients with neovascular age-related macular degeneration (nAMD), including delays in care and economic impacts. Methods: A retrospective observational cohort study analyzed participants with nAMD in the IRIS (Intelligent Research in Sight) Registry who were treated with antivascular endothelial growth factor agents from 2015 to 2024. Four cohorts were analyzed: (1) bevacizumab only, (2) bevacizumab transitioned to a biosimilar, (3) bevacizumab transitioned to a branded agent, and (4) bevacizumab transitioned to a biosimilar and then to a branded agent. The main outcome measures were number of intravitreal injection events, transitions in medications, and injection intervals. Results: A total of 182 757 eyes with nAMD met inclusion criteria: 136 451 received bevacizumab only; 2184, bevacizumab followed by a biosimilar; 335, bevacizumab followed by a biosimilar, followed by branded medication; and 43 787, bevacizumab followed by a branded agent. Newer agents (faricimab and aflibercept 8 mg) experienced additional delays between transitions (mean of 8.6 days) compared with aflibercept 2 mg ( P < .001). Economic modeling based on IRIS medication transition rates and medication cost showed that bevacizumab transitioned to a biosimilar and then to a branded agent was 36.3% and 11.62% more costly than bevacizumab transitioned to a biosimilar ( P < .001) and bevacizumab transitioned to a branded agent ( P < .001), respectively, within 2 years. Similar cost differences persisted in 5- and 10-year projections. Bevacizumab transitioned to a biosimilar and then to a branded agent was the costliest pathway compared with transitions to biosimilars and branded agents, regardless of which branded agent was used. Conclusions: IRIS Registry cohort data suggest possible demographic differences in patients undergoing medication transitions, including biosimilar agents, as well as delays in care with medication transitions. Economic simulations suggest that multiple transitions may be more costly than direct transitions from bevacizumab to either biosimilar or branded agents.


  • Forecasting the Workforce of Uveitis Specialists

    by Anika Shah, Sean T. Berkowitz, Edmund Tsui, John A. Gonzales, Eric L. Crowell, Sapna Gangaputra


  • Open Access

    Volumetric Optical Coherence Tomography Analysis of Visual and Surgical Outcomes in Patients With Full-Thickness Macular Hole

    by Russel H. Dinh, Howard Zhang, Rebecca Pan, Jose Rico-Jimenez, Shravika Lam, Xiangyu Ji, Margaret Comer, Farozan Noori, Sean Berkowitz, Mohsin H. Ali, et al.

    Purpose: To investigate the relationship between preoperative volumetric optical coherence tomography (OCT) features of full-thickness macular holes (FTMHs), including intraretinal cysts and 3-dimensional hole symmetry, and both visual acuity outcomes and surgical prognosis in patients with FTMH. Methods : This multicenter, retrospective cohort study assessed patients with FTMH who underwent pars plana vitrectomy from 2017 to 2022. In-depth manual segmentation of each pre- and postoperative OCT volumetric scan (60 B-scans per volume) was performed by 3 graders. Correlations between preoperative cystoid volume and FTMH symmetry and preoperative visual acuity, preoperative minimum linear diameter (MLD), improvement in visual acuity at 6 months postsurgery, and FTMH closure rate postsurgery were assessed using linear regression models, adjusted for baseline lens status, duration of symptoms, and MLD. Results: A total of 69 eyes of 69 patients with FTMH were included. Mean (± SD) visual acuity was 0.69 ± 0.44 logMAR (Snellen 20/98) before surgery, and improved to 0.39 ± 0.23 logMAR at 6 months after surgery (Snellen 20/49). FTMH closure after a single surgery was 96%. Greater cystoid volume before surgery was associated with larger FTMH MLD ( P < .001), worse preoperative visual acuity ( P = .003), and greater visual acuity improvement at 6 months after surgery ( P = .02). Greater hole asymmetry before surgery was associated with smaller MLD ( P = .04), but not associated with preoperative visual acuity ( P = .74) or postoperative FTMH closure rates ( P = .19). Conclusions: This study on OCT volumetric measurements showed that intraretinal cystoid volume correlated with larger macular holes and greater visual acuity improvement while smaller macular holes tended to be more asymmetric.

  • Open Access

    A Time-Driven Activity-Based Costing Analysis of New Uveitis Patient Visits

    by Sean T. Berkowitz, Avni P. Finn, Akshay S. Thomas, Lish Nore, Regina Akin, Sapna Gangaputra

    Purpose: To use time-driven activity-based costing to calculate the complete cost profile of new uveitis patient visits. Methods: A multicenter cohort of consecutive patients referred for new uveitis evaluation, including all anatomic locations of uveitis, was included for economic analysis. Process flow mapping, electronic health record time logs, and manual validation were used for time-driven activity-based costing analysis. Imaging time and resources, which are billed separately, were excluded. Results: Time-driven activity-based costing analysis of new uveitis patient visits resulted in an average total cost of $550.50 per visit, including $56.78 of overhead (95% CI, $493.74 to $607.27). On average, patient visits required 36.6 minutes of physician time pre-visit, 30.1 minutes during the visit, and 31.7 minutes post-visit. Relative to Medicare reimbursement, the average cost resulted in losses of $325.78 for Current Procedural Terminology (CPT) code 99205 and $380.16 for CPT code 99204. The G2211 add-on CPT code compensated for 3.23 minutes of in-visit physician time. Conclusions: The cost of new uveitis patient visits exceeds maximum Medicare reimbursement in both academic and private practice settings. These findings may inform policy discussions on reimbursement to better reflect the time and expertise required for complex uveitis patient evaluation and management.


  • The use of time-driven activity-based costing in ophthalmology: A scoping review

    by Howard Y. Zhang, Aden W. Smith, Heather E. Laferriere, Avni P. Finn, Sean T. Berkowitz

  • Open Access

    Time-Driven Activity-BasedCosting Analysis of Panretinal Photocoagulation

    by Sean T. Berkowitz, David L. Zhang, Warren W. Pan, Osama Ahmed, Cagri G. Besirli, Nicolaas P. DeRuyter, Tahreem A. Mir, Russel H. Dinh, Mark W. Johnson, Avni P. Finn


  • Top Cited Papers

    Ophthalmology Workforce Projections in the United States, 2020 to 2035

    by Sean T. Berkowitz, Avni P. Finn, Ravi Parikh, Ajay E. Kuriyan, Shriji Patel


  • Cost-Efficacy in the Study of Comparative Treatments for Retinal Vein Occlusion 2—Should We Consider Step Therapy for Retinal Vein Occlusion?

    by Sean T. Berkowitz, Avni P. Finn

    Retinal vein occlusions (RVOs) cause substantial vision loss and visual impairment in the working-age population, and disease burden is growing with an estimated 28.06 million people affected worldwide in 2015.1 Restoring and maintaining vision for RVO typically is reliant on frequent costly treatments and close surveillance, with anti–vascular endothelial growth factor (VEGF) agents often used as first-line treatments for the sequelae of RVO including macular edema and neovascularization. This large treatment and surveillance burden coupled with the cost of treatment options motivates cost-effectiveness analyses such as that performed by Kymes et al2 evaluating repackaged (compounded) bevacizumab compared with aflibercept for the treatment of macular edema associated with central RVO (CRVO) or hemiretinal RVO (HRVO).